Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Atypical Antipsychotic Drug Asenapine Significantly Improves Symptoms of Schizophrenia in PIII Trial; Meiji Seika Pharma
May 30, 2014
- Introduction of Joint Bidding System to Result in 100% Price Agreement Rate by September: Mr Takada of Qol
May 30, 2014
- Eisai Receives Positive Opinion from CHMP on Expanded Indication for Halaven for Second-Line Treatment of Advanced Breast Cancer
May 30, 2014
- Shire Japan to Independently Launch Orphan Drug around September
May 29, 2014
- NDA for Once-Yearly Zoledronic Acid Injection Expected in FY2015: Asahi Kasei Pres. Asano
May 29, 2014
- Daiichi Sankyo’s Antiplatelet Agent Efient Now Available in Japan
May 28, 2014
- Novartis to Divest Flu Vaccine Biz within 18 Months
May 28, 2014
- DSP Grants Daiichi Sankyo Commercialization Rights to Lurasidone in South America
May 28, 2014
- GSK Files Long-Acting COPD Drug for Approval in Japan
May 27, 2014
- Taisho Toyama to Center on Safety for Lusefi Promotion: Product Manager
May 27, 2014
- GSK Launches Tenozet, a First-Line Option for the Treatment of Chronic Hepatitis B
May 27, 2014
- DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
May 27, 2014
- Concurrent Use Restrictions Lifted for 3 DPP-4 Inhibitor Products
May 27, 2014
- Chugai Concludes Deal with Roche for Chugai’s Antibody Engineering Technologies
May 27, 2014
- Daiichi Sankyo, US Research Institute to Collaborate in Developing Cardiovascular-Metabolic Disease Treatments
May 26, 2014
- 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
- Astellas Launches Anticancer Drug Xtandi Capsules in Japan
May 26, 2014
- Three Companies Including DSP Jointly Invest 845 Million Yen in Create Vaccine
May 26, 2014
- Teikoku Seiyaku Licenses Antiallergic Treatment from Uriach of Spain
May 26, 2014
- Foreign Drug Makers’ Japan Units Underperform Market Growth in 2013
May 23, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…